The high cost of energy in the UK is having a negative impact on drug and chemical firms' ability to compete according to manufacturers quizzed by the Chemical Industries Association (CIA).
Economic uncertainty and a bleak fiscal outlook will lead to over-regulation and increased fines in the clinical trial industry, according to an economic expert at PCT.
US authorities will soon have a new system capable of tracking drugs from the factory floor to the pharmacy shelf after the Senate passed the “Drug Quality and Security Bill” last night.
AstraZeneca says it would never outsource the manufacture of Zoladex after announcing plans to invest £120m ($190m) in a fifth production facility for the blockbuster cancer drug.
Novartis has confirmed it is closing a UK facility as part of a global R&D review but remains silent on rumours specific business units will be divested.
API, drug intermediates and formulations firm Granules India ended the second quarter of fiscal 2013 with higher revenue and profit thanks to gains made by all three of its units.
Regulatory pressure for risk-based supply chain management is increasing excipient suppliers’ audit burden according to the team preparing to launch the 'excipact' certification scheme as an independent association.
Indian manufacturing heavyweight Mylan Laboratories is looking to build off its major acquisition of Agila with a number of smaller acquisitions, while Natco is about to receive a cash infusion for manufacturing expansions.
Azelis says its partnership with JH Nanhang (JHNH) will feed a large demand for polyvinylpyrolidones (PVP) excipients and bring the China-made ingredients to new markets.
Parexel has teamed up with Japanese trial management services firm Fuijitsu Systems West in an agreement that underlines the CROs eClinical growth ambitions in Asia.
Bliss GVS says allegations of supplying fake medicines and a blanket ban imposed on its products by the Food and Drugs Authority Ghana (FDA) are both “harsh” and “baffling.”
In the wake of recent bribery scandals, Boehringer Ingelheim (B-I) has called for stricter regulations in China, as it plans to triple production at its Shanghai manufacturing site.
Rapid growth in demand for pharmaceutical storage solutions could lead to Yusen working with its competitors, the firm says as it opens a 40,000m2 warehouse in Thailand.
CROs across the board saw revenue increase by more than 10% between 2011 and 2012, which was largely fuelled by Quintiles' growth, according to a new report.
The TransCelerate BioPharma industry group has launched its clinical trial comparator network to establish a reliable means for sourcing quality drugs for clinical trials.
Ireland-based commercialization services firm United Drug has announced plans to buy Spanish contract pharmaceutical sales group Expansis for €12m ($15m).
Integrated DNA Technologies (IDT) has opened a facility in Singapore in order to manufacture oligonucleotides for research companies throughout the region.
The current US shortage of tetracycline is not likely to be resolved any time soon because of ongoing manufacturing and raw material supply issues according to the US FDA.
As GlaxoSmithKline, Bristol-Myers Squibb and Novartis are embroiled in alleged bribery and data falsification in Asia, CROs will have to a take a hard look at whether their investments in the region will pay off as quickly as they once thought.
Ernst & Young (E&Y) analysts will try to illuminate the Sunshine Act for Greenphire's customers in the third collaboration the trial payment technology firm has signed in as many weeks.
A consortium of European vaccine experts, including the Swiss CRO Preclin Biosystems, has received almost €5.5m ($7.1m) from the EU to develop a vaccine against the deadly MRSA bacteria.
Chinese oversight of API plants is improving, but it is still important EU importers choose their sources carefully says European Medicines Agency (EMA) collaboration chief, Emer Cooke.
